Top of page
Global Site Navigation

Centre for Precision Health - ECU Strategic Research Centre

Local Section Navigation
You are here: Main Content

Comparison of Autoantibodies with Circulating-Tumour DNA, to Predict and Monitor Clinical Response to Pembrolizumab in Late-Stage Melanoma Patients

Student name: 

Rebecca Auzins is a Masters by Research candidate and Research Assistant in the cancer program.

Supervisors:

  1. Dr Pauline Zaenker
  2. Professor Elin Gray

Summary of thesis:

Predictive biomarkers of response with accurate sensitivity are currently in high demand. While there are treatment options available for patients with late-stage melanoma, they do not always successfully produce a response. With ctDNA at the forefront of current biomarker research, its use is limited to patients which present with known tumour-specific mutations, unlike autoantibodies, which have shown promising results as cancer biomarkers, however, their efficacy as predictors of response has not been thoroughly researched. This project will aim to identify an autoantibody that is indicative of response for late-stage melanoma patients undergoing immunotherapy treatments.

Skip to top of page